Drug Trial Radar · NCT06813365
Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)
Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Jun 12, 2024
Primary completion
Oct 30, 2027
Study completion Dec 30, 2028
Sponsor
- Lead sponsor
- Dizal PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Feb 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to evaluate safety and antitumor activity of DZD6008 in patients with advanced NSCLC with EGFR mutations. This is the first time the drug is tested in human.
Conditions
- Nonsmall-cell Lung Cancer
Interventions
DZD6008Drug
Daily dose of DZD6008
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: To assess safety and tolerabilityTime frame: 21 days after the first multiple dose.
- Part A: To assess safety and tolerabilityTime frame: Through the study completion, an average of around 1 year.
- Part B: To assess anti-tumor activityTime frame: Through the study completion, an average of around 1 year.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.